Jianjin Huang
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).
Journal: Future oncology (London, England)
Published: December 04, 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.
Journal: Journal for immunotherapy of cancer
Published: October 10, 2024
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.
Journal: Signal transduction and targeted therapy
Published: August 25, 2024
Phase Ib study of the oral PI3Kδ inhibitor linperlisib in patients with advanced solid tumors.
Journal: International journal of clinical oncology
Published: July 26, 2024
Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.
Journal: Cancer cell
Published: January 03, 2024
Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial.
Journal: Journal of thoracic disease
Published: November 12, 2022
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 11, 2022
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 07, 2022
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.
Journal: BMC medicine
Published: October 12, 2021
Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 13, 2021
Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China.
Journal: Chinese clinical oncology
Published: May 13, 2020
Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study.
Journal: Journal of thoracic disease
Published: April 11, 2020
Last Updated: 09/26/2026